Revolution and outlook of interventional therapy for valvular heart disease: technological innovation driving the future
-
摘要: 心脏瓣膜病已成为全球范围内的重要健康问题，尤其在老龄化社会中，其发病率和病死率持续上升。在中国，随着人口老龄化的加剧，心脏瓣膜病的负担愈加沉重。传统的外科手术在治疗高龄或伴有多种合并症的患者时，存在较高风险。近年来，经导管介入治疗技术取得了显著进展，成为全球心脏瓣膜病治疗的重要选择。本文综述了近年来心脏瓣膜病介入治疗的最新进展，包括关键研究、技术创新、临床应用以及未来研究的方向。经导管主动脉瓣置换技术的不断拓展和经导管二、三尖瓣介入治疗的成功应用使得心脏瓣膜病的治疗手段更加多样化，且国产器械在全球临床试验中的应用也日益增多，展示了中国在这一领域的技术突破和市场潜力。未来，随着多组学与人工智能的结合、新型瓣膜器械的发展和无植入治疗的突破等，心脏瓣膜病的介入治疗将在精准性、安全性和耐久性方面取得进一步提升。Abstract: Valvular heart disease(VHD) has become a significant global health issue, with its incidence and mortality continuously rising, particularly in aging society. In China, the burden of VHD has grown increasingly heavier due to the aging population. Traditional surgical interventions carry high risks when treating elderly patients or those with multiple comorbidities. In recent years, transcatheter interventions have made significant progress, becoming an important treatment option for VHD worldwide. This review summarizes the latest advancements in interventional therapy for VHD, including key studies, technological innovations, clinical applications, and future research directions. The ongoing promotion of transcatheter aortic valve replacement technology and the successful application of transcatheter mitral and tricuspid intervention treatments have diversified the available therapeutic options for VHD. Additionally, the growing use of domestic devices in global clinical trials highlights China's technological breakthroughs and market potential in this field. In the future, with the integration of multi-omics and artificial intelligence, the development of novel valve devices, and breakthroughs in non-implantable treatments, interventional therapies for VHD are expected to achieve further improvements in precision, safety, and durability.
-
-
[1] Coffey S, Roberts-Thomson R, Brown A, et al. Global epidemiology of valvular heart disease[J]. Nat Rev Cardiol, 2021, 18(12): 853-864. doi: 10.1038/s41569-021-00570-z
[2] Xu H, Liu Q, Cao K, et al. Distribution, Characteristics, and Management of Older Patients With Valvular Heart Disease in China: China-DVD Study[J]. JACC Asia, 2022, 2(3): 354-365. doi: 10.1016/j.jacasi.2021.11.013
[3] 国家心血管病中心, 中国心血管健康与疾病报告编写组, 胡盛寿. 中国心血管健康与疾病报告2023概要[J]. 中国循环杂志, 2024, 39(7): 625-660.
[4] 国家心血管病中心, 国家结构性心脏病介入质控中心, 中华医学会心血管病学分会, 等. 经导管主动脉瓣置换术临床实践指南[J]. 中华医学杂志, 2023, 103(12): 886-900. doi: 10.3760/cma.j.cn112137-20221106-02332
[5] Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2021, 143(5): e35-e71.
[6] Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease[J]. Eur Heart J, 2022, 43(7): 561-632. doi: 10.1093/eurheartj/ehab395
[7] Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients[J]. N Engl J Med, 2019, 380(18): 1695-1705. doi: 10.1056/NEJMoa1814052
[8] Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients[J]. N Engl J Med, 2019, 380(18): 1706-1715. doi: 10.1056/NEJMoa1816885
[9] Genereux P, Schwartz A, Oldemeyer JB, et al. Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis[J]. N Engl J Med, 2025, 392(3): 217-227. doi: 10.1056/NEJMoa2405880
[10] Van Mieghem NM, Elmariah S, Spitzer E, et al. Transcatheter Aortic Valve Replacement in Patients With Systolic Heart Failure and Moderate Aortic Stenosis[J]. J Am Coll Cardiol, 2024, S0735-1097(24)09960-1.
[11] Loganath K, Craig NJ, Everett RJ, et al. Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis: The EVOLVED Randomized Clinical Trial[J]. JAMA, 2025, 333(3): 213-221. doi: 10.1001/jama.2024.22730
[12] Banovic M, Putnik S, Da CB, et al. Aortic valve replacement vs. conservative treatment in asymptomatic severe aortic stenosis: long-term follow-up of the AVATAR trial[J]. Eur Heart J, 2024, 45(42): 4526-4535. doi: 10.1093/eurheartj/ehae585
[13] Blankenberg S, Seiffert M, Vonthein R, et al. Transcatheter or Surgical Treatment of Aortic-Valve Stenosis[J]. N Engl J Med, 2024, 390(17): 1572-1583. doi: 10.1056/NEJMoa2400685
[14] Jørgensen TH, Thyregod HGH, Savontaus M, et al. Transcatheter aortic valve implantation in low-risk tricuspid or bicuspid aortic stenosis: the NOTION-2 trial[J]. Eur Heart J, 2024, 45(37): 3804-3814. doi: 10.1093/eurheartj/ehae331
[15] Vahl TP, Thourani VH, Makkar RR, et al. Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation(ALIGN-AR): a prospective, multicentre, single-arm study[J]. Lancet, 2024, 403(10435): 1451-1459. doi: 10.1016/S0140-6736(23)02806-4
[16] Wei L, Liu H, Zhu L, et al. A New Transcatheter Aortic Valve Replacement System for Predominant Aortic Regurgitation Implantation of the J-Valve and Early Outcome[J]. JACC Cardiovasc Interv, 2015, 8(14): 1831-1841. doi: 10.1016/j.jcin.2015.08.021
[17] 中国医师协会心血管内科医师分会结构性心脏病学组, 周达新, 吴永健. 单纯主动脉瓣反流经股动脉主动脉瓣置换中国专家共识2023[J]. 中国介入心脏病学杂志, 2023, 31(11): 801-809. doi: 10.3969/j.issn.1004-8812.2023.11.001
[18] Stone GW, Abraham WT, Lindenfeld J, et al. Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation[J]. N Engl J Med, 2023, 388(22): 2037-2048. doi: 10.1056/NEJMoa2300213
[19] Wang J, Liu X, Pu Z, et al. Safety and efficacy of the DragonFly system for transcatheter valve repair of degenerative mitral regurgitation: one-year results of the DRAGONFLY-DMR trial[J]. EuroIntervention, 2024, 20(4): e239-e249. doi: 10.4244/EIJ-D-23-00361
[20] Anker SD, Friede T, von Bardeleben RS, et al. Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation[J]. N Engl J Med, 2024, 391(19): 1799-1809. doi: 10.1056/NEJMoa2314328
[21] Baldus S, Doenst T, Pfister R, et al. Transcatheter Repair versus Mitral-Valve Surgery for Secondary Mitral Regurgitation[J]. N Engl J Med, 2024, 391(19): 1787-1798. doi: 10.1056/NEJMoa2408739
[22] Rogers JH, Asch F, Sorajja P, et al. Expanding the Spectrum of TEER Suitability: Evidence From the EXPAND G4 Post Approval Study[J]. JACC Cardiovasc Interv, 2023, 16(12): 1474-1485. doi: 10.1016/j.jcin.2023.05.014
[23] Urena M, Lurz P, Sorajja P, et al. Transcatheter mitral valve implantation for native valve disease[J]. EuroIntervention, 2023, 19(9): 720-738. doi: 10.4244/EIJ-D-22-00890
[24] Ludwig S, Granada JF. Transcatheter mitral valve replacement at an inflection point: lessons learned and the path forward[J]. Eur Heart J, 2024, 45(20): 1776-1778. doi: 10.1093/eurheartj/ehae013
[25] Hahn RT, Makkar R, Thourani VH, et al. Transcatheter Valve Replacement in Severe Tricuspid Regurgitation[J]. N Engl J Med, 2025, 392(2): 115-126. doi: 10.1056/NEJMoa2401918
[26] Stolz L, Cheung A, Boone R, et al. Transjugular Transcatheter Tricuspid Valve Replacement: Early Compassionate Use Outcomes[J]. JACC Cardiovasc Interv, 2024, 17(16): 1936-1945. doi: 10.1016/j.jcin.2024.06.014
[27] Sorajja P, Whisenant B, Hamid N, et al. Transcatheter Repair for Patients with Tricuspid Regurgitation[J]. N Engl J Med, 2023, 388(20): 1833-1842. doi: 10.1056/NEJMoa2300525
[28] Lurz P, Rommel KP, Schmitz T, et al. Real-World 1-Year Results of Tricuspid Edge-to-Edge Repair From the bRIGHT Study[J]. J Am Coll Cardiol, 2024, 84(7): 607-616. doi: 10.1016/j.jacc.2024.05.006
[29] Wild MG, Stolz L, Rosch S, et al. Transcatheter Valve Repair for Tricuspid Regurgitation: 1-Year Results From a Large European Real-World Registry[J]. J Am Coll Cardiol, 2025, 85(3): 220-231. doi: 10.1016/j.jacc.2024.10.068
[30] Blaser MC, Buffolo F, Halu A, et al. Multiomics of Tissue Extracellular Vesicles Identifies Unique Modulators of Atherosclerosis and Calcific Aortic Valve Stenosis[J]. Circulation, 2023, 148(8): 661-678. doi: 10.1161/CIRCULATIONAHA.122.063402
[31] Ren T, Maitusong M, Zhou X, et al. Programing Cell Assembly via Ink-Free, Label-Free Magneto-Archimedes Based Strategy[J]. ACS Nano, 2023, 17(13): 12072-12086. doi: 10.1021/acsnano.2c10704
[32] Cheng S, Liu X, Qian Y, et al. Double-Network Hydrogel Armored Decellularized Porcine Pericardium as Durable Bioprosthetic Heart Valves[J]. Adv Healthc Mater, 2022, 11(8): e2102059. doi: 10.1002/adhm.202102059
-
计量
- 文章访问数: 615
- 施引文献: 0
下载: